Ascendis Pharma A/S Current Contract Liabilities
Ascendis Pharma A/S (ASND) had Current Contract Liabilities of EUR 4.94 million as of 2025-12-31, per its 20-F filed 2026-02-11.
Financial Statements › Notes
ifrs-full:CurrentContractLiabilities · last filed 2026-02-11
- 2025-12-31: Current Contract Liabilities 4.94M EUR.
- 2025-09-30: Current Contract Liabilities 4.16M EUR.
- 2025-06-30: Current Contract Liabilities 1.79M EUR.
- 2025-03-31: Current Contract Liabilities 1.19M EUR.
| Period end | Current Contract Liabilities |
|---|---|
| 2025-12-31 | 4.94M EUR 20-F · filed 2026-02-11 |
| 2025-09-30 | 4.16M EUR 6-K · filed 2025-11-12 |
| 2025-06-30 | 1.79M EUR 6-K · filed 2025-08-07 |
| 2025-03-31 | 1.19M EUR 6-K · filed 2025-05-01 |
| 2024-12-31 | 936.00K EUR 20-F · filed 2026-02-11 |
| 2024-09-30 | 1.59M EUR 6-K · filed 2024-11-14 |
| 2024-06-30 | 1.29M EUR 6-K · filed 2024-09-03 |
| 2024-03-31 | 1.18M EUR 6-K · filed 2024-05-02 |
| 2023-12-31 | 1.18M EUR 20-F · filed 2025-02-12 |
| 2023-09-30 | 4.03M EUR 6-K · filed 2023-11-07 |
| 2023-06-30 | 4.15M EUR 6-K · filed 2023-09-05 |
| 2023-03-31 | 10.00M EUR 6-K · filed 2023-04-27 |
| 2023-01-01 | 0.00 EUR 20-F · filed 2025-02-12 |
| 2022-12-31 | 0.00 EUR 20-F · filed 2024-02-07 |
| 2022-09-30 | 3.14M EUR 6-K · filed 2022-11-02 |
| 2022-06-30 | 0.00 EUR 6-K · filed 2022-08-10 |
| 2022-03-31 | 265.00K EUR 6-K · filed 2022-05-11 |
| 2021-12-31 | 2.60M EUR 20-F · filed 2023-02-16 |
| 2021-09-30 | 36.00K EUR 6-K · filed 2021-11-10 |
| 2021-06-30 | 145.00K EUR 6-K · filed 2021-08-27 |
| 2021-03-31 | 254.00K EUR 6-K · filed 2021-05-27 |
| 2020-12-31 | 363.00K EUR 20-F · filed 2022-03-02 |
| 2020-09-30 | 223.00K EUR 6-K · filed 2020-11-12 |
| 2020-03-31 | 343.00K EUR 6-K · filed 2020-05-19 |
| 2019-12-31 | 858.00K EUR 20-F · filed 2021-03-10 |
| 2019-09-30 | 1.37M EUR 6-K · filed 2019-11-18 |
| 2019-06-30 | 2.16M EUR 6-K · filed 2019-08-28 |
| 2019-03-31 | 3.07M EUR 6-K · filed 2019-05-30 |
| 2018-12-31 | 6.90M EUR 20-F · filed 2020-04-03 |
| 2017-12-31 | 0.00 EUR 20-F · filed 2019-04-03 |